Increased Level of Vascular Endothelial Growth Factors by 4-hexylresorcinol is Mediated by Transforming Growth Factor-β1 and Accelerates Capillary Regeneration in the Burns in Diabetic Animals.
Animals
Burns
/ complications
Diabetes Mellitus, Experimental
/ complications
Disease Models, Animal
Human Umbilical Vein Endothelial Cells
Humans
Macrophages
/ metabolism
RNA, Small Interfering
/ genetics
Rats
Receptor, Transforming Growth Factor-beta Type I
/ genetics
Resorcinols
/ pharmacology
Signal Transduction
/ drug effects
Transforming Growth Factor beta1
/ genetics
Vascular Endothelial Growth Factor A
/ genetics
Vascular Endothelial Growth Factor C
/ genetics
Wound Healing
/ drug effects
4-hexylresorcinol
HUVEC
TGF-β1
angiogenesis
diabetes mellitus
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
22
04
2020
revised:
11
05
2020
accepted:
12
05
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
12
2
2021
Statut:
epublish
Résumé
4-Hexyl resorcinol (4HR) is an organic compound and has been used in skin care application. 4HR is an M2-type macrophage activator and elevates vascular endothelial growth factor (VEGF) expression via the hypoxia-inducible factor (HIF)-independent pathway. As endothelial cells are important in wound healing, the human umbilical vein endothelial cells (HUVECs) were treated with 4HR, and changes in VEGF-A, -C, and transforming growth factor-β1 (TGF-β1) expression were investigated. The administration of 4HR increased the expression level of VEGF-A, -C, and TGF-β1. The application of TGF-β1 protein also increased the expression level of VEGF-A and -C. Knockdown with small interfering RNA (siRNA) targeting to TGF-β1 and the selective chemical inhibition (A83-01) to ALK5 confirmed the involvement of the TGF-β signaling pathway in the 4-HR-mediated VEGFs expression. 4HR application in a burn model of diabetic rats demonstrated an increased level of angiogenic proteins with wound healing. Compared to sericin application, the 4HR application group showed more prominent capillary regeneration. Collectively, 4HR activated TGF-β1/ALK5/VEGFs signaling in endothelial cells and induced vascular regeneration and remodeling for wound healing.
Identifiants
pubmed: 32423083
pii: ijms21103473
doi: 10.3390/ijms21103473
pmc: PMC7279008
pii:
doi:
Substances chimiques
RNA, Small Interfering
0
Resorcinols
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
VEGFC protein, human
0
Vascular Endothelial Growth Factor A
0
Vascular Endothelial Growth Factor C
0
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
TGFBR1 protein, human
EC 2.7.11.30
resorcinol
YUL4LO94HK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Rural Development Administration
ID : PJ01313902
Références
Lancet. 2003 May 3;361(9368):1545-51
pubmed: 12737879
Maxillofac Plast Reconstr Surg. 2020 Mar 5;42(1):5
pubmed: 32206664
Sci Rep. 2019 Mar 4;9(1):3379
pubmed: 30833641
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1997 Sep;11(5):257-60
pubmed: 9867922
Cancer Sci. 2005 Nov;96(11):791-800
pubmed: 16271073
Burns. 2018 Mar;44(2):386-396
pubmed: 29032969
Clin Sci (Lond). 2004 Dec;107(6):519-32
pubmed: 15324298
Sci Rep. 2019 Mar 5;9(1):3448
pubmed: 30837602
Oncol Rep. 2012 Aug;28(2):677-81
pubmed: 22664654
Maxillofac Plast Reconstr Surg. 2018 Nov 22;40(1):34
pubmed: 30525010
Exp Eye Res. 2017 Nov;164:74-81
pubmed: 28803935
Int J Mol Sci. 2018 Mar 15;19(3):
pubmed: 29543707
J Trauma. 2000 Aug;49(2):327-30
pubmed: 10963547
Endothelium. 2004 Mar-Apr;11(2):89-97
pubmed: 15370068
Arch Dermatol Res. 2013 Aug;305(6):555
pubmed: 23812437
Burns. 2016 Nov;42(7):1534-1541
pubmed: 27198070
Tissue Eng Part A. 2010 May;16(5):1457-68
pubmed: 19938961
Int J Burns Trauma. 2015 Mar 20;5(1):13-21
pubmed: 26064798
Chem Res Toxicol. 2009 Jan;22(1):52-63
pubmed: 19063592
J Am Acad Dermatol. 2014 Jan;70(1):1.e1-18; quiz 19-20
pubmed: 24355275
Cardiovasc Diabetol. 2008 Apr 19;7:8
pubmed: 18423039
Int J Mol Sci. 2017 Jul 03;18(7):
pubmed: 28671607
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Int J Mol Sci. 2020 Feb 24;21(4):
pubmed: 32102282
Skin Res Technol. 2019 Mar;25(2):118-123
pubmed: 30030915
FEBS Lett. 2012 Nov 16;586(22):3951-5
pubmed: 23058288
Biomaterials. 2015 Jan;37:194-207
pubmed: 25453950
Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F167-F180
pubmed: 28978530
Burns. 2016 Dec;42(8):1734-1739
pubmed: 27338180
Maxillofac Plast Reconstr Surg. 2019 Jul 23;41(1):26
pubmed: 31403036